The storm has cleared: lessons from the CD28 superagonist TGN1412 trial
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
The life-threatening cytokine-release syndrome suffered by six volunteers in a Phase I clinical trial following administration of the CD28 superagonist antibody TGN1412 (developed by TeGenero) in March 2006 was completely unpredicted by the preclinical studies. Here, Thomas Hünig, main founder of TeGenero, describes the recent investigations into what went wrong and discusses the lessons learnt for future clinical trials.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063842 · Cited by 2,164
Self-recognition promotes the foreign antigen sensitivity of naive T lymphocytes
Stefanová, I., Dorfman, J. R., & Germain, R. N. (2002) · Nature · doi:10.1038/nature01146 · Cited by 389
ABRAMOWICZ, D., SCHANDENE, L., GOLDMAN, M., CRUSIAUX, A., VEREERSTRAETEN, P., PAUW, L. D., WYBRAN, J., KINNAERT, P., DUPONT, E., & TOUSSAINT, C. (1989) · Transplantation · doi:10.1097/00007890-198904000-00008 · Cited by 352
Eastwood, D., Findlay, L., Poole, S., Bird, C., Wadhwa, M., Moore, M., Burns, C., Thorpe, R., & Stebbings, R. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00922.x · Cited by 300
Beyersdorf, N., Gaupp, S., Balbach, K., Schmidt, J., Toyka, K. V., Lin, C.-H., Hanke, T., Hünig, T., Kerkau, T., & Gold, R. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20051060 · Cited by 203
Efficient expansion of regulatory T cells in vitro and in vivo with a CD28 superagonist
Lin, C., & Hünig, T. (2003) · European Journal of Immunology · doi:10.1002/eji.200323570 · Cited by 184
Self-citationTacke, M., Hanke, G., Hanke, T., & Hünig, T. (1997) · European Journal of Immunology · doi:10.1002/eji.1830270136 · Cited by 163
Self-citationRömer, P. S., Berr, S., Avota, E., Na, S.-Y., Battaglia, M., ten Berge, I., Einsele, H., & Hünig, T. (2011) · Blood · doi:10.1182/blood-2010-12-319780 · Cited by 153
Self-citationRapid Regulatory T-Cell Response Prevents Cytokine Storm in CD28 Superagonist Treated Mice
Gogishvili, T., Langenhorst, D., Lühder, F., Elias, F., Elflein, K., Dennehy, K. M., Gold, R., & Hünig, T. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004643 · Cited by 79
Self-citationHanke, T. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69651-7 · Cited by 65
Cited by
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Galon, J., & Bruni, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0007-y · Cited by 3,409
CD28 Costimulation: From Mechanism to Therapy
Esensten, J. H., Helou, Y. A., Chopra, G., Weiss, A., & Bluestone, J. A. (2016) · Immunity · doi:10.1016/j.immuni.2016.04.020 · Cited by 937
Dietary fatty acids directly impact central nervous system autoimmunity via the small intestine
Haghikia, A., Jörg, S., Duscha, A., Berg, J., Manzel, A., Waschbisch, A., Hammer, A., Lee, D.-H., May, C., Wilck, N., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.09.007 · Cited by 927
“, 2005) but not practically feasible outside of controlled experimental conditions (Hünig, 2012).”
Animal models of human disease: challenges in enabling translation
McGonigle, P., & Ruggeri, B. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.08.006 · Cited by 610
Ischemic stroke: experimental models and reality
Sommer, C. J. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1667-0 · Cited by 599
“In contrast to CD4+, T cells of humans expressing CD28 macaques lost CD28 expression of CD4+ T cells during differentiation [58].”
ResultDustin, M. L. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0161 · Cited by 502
“It is not clear if this happens physiologically, but the phenomenon may be useful in a clinical setting if it can be controlled and directed (109).”
BackgroundIntratumoral immunotherapy: using the tumor as the remedy
Marabelle, A., Tselikas, L., de Baere, T., & Houot, R. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx683 · Cited by 375
“agonistic antiCD28 or anti-CD137 mAbs) [58, 59].”
The promise and challenges of immune agonist antibody development in cancer
Mayes, P. A., Hance, K. W., & Hoos, A. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.75 · Cited by 355
Delivering safer immunotherapies for cancer
Milling, L., Zhang, Y., & Irvine, D. J. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.05.011 · Cited by 305
“densities promoting extensive cell-cell contacts as in lymphoid tissues [105].”
Role of Lymphocytes in Myocardial Injury, Healing, and Remodeling After Myocardial Infarction
Hofmann, U., & Frantz, S. (2015) · Circulation Research · doi:10.1161/circresaha.116.304072 · Cited by 296
“Phase I clinical trial of superagonistic anti-CD28 antibody in humans produced catastrophic effects for several reasons.(103,104)”
BackgroundFessas, P., Lee, H., Ikemizu, S., & Janowitz, T. (2017) · Seminars in Oncology · doi:10.1053/j.seminoncol.2017.06.002 · Cited by 255
“For example, different CD28 agonist antibodies with similar preclinical data showed extreme differences in clinical profiles [34].”
BackgroundThe Evolving Role of CD8+CD28− Immunosenescent T Cells in Cancer Immunology
Huff, W. X., Kwon, J. H., Henriquez, M., Fetcko, K., & Dey, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112810 · Cited by 217
“Investigation of these unexpected serious adverse events have led to better design of clinical trials and appreciation of differences in CD28 expression and regulation between species (critical for transitioning preclinical testing to clinical investigations) [64,65].”
BackgroundSanmamed, M. F., Pastor, F., Rodriguez, A., Perez-Gracia, J. L., Rodriguez-Ruiz, M. E., Jure-Kunkel, M., & Melero, I. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.05.014 · Cited by 190
van de Ven, K., & Borst, J. (2015) · Immunotherapy · doi:10.2217/imt.15.32 · Cited by 177
Too Much of a Good Thing? Tim-3 and TCR Signaling in T Cell Exhaustion
Ferris, R. L., Lu, B., & Kane, L. P. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400557 · Cited by 173
Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications
Buqué, A., Bloy, N., Aranda, F., Castoldi, F., Eggermont, A., Cremer, I., Fridman, W. H., Fucikova, J., Galon, J., Marabelle, A., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1008814 · Cited by 129
Na, S., Mracsko, E. Z., Liesz, A., Hünig, T., & Veltkamp, R. C. (2014) · Stroke · doi:10.1161/strokeaha.114.007756 · Cited by 128
Self-citationUnderstanding the CD28/CTLA-4 (CD152) Pathway and Its Implications for Costimulatory Blockade
Gardner, D., Jeffery, L. E., & Sansom, D. M. (2014) · American Journal of Transplantation · doi:10.1111/ajt.12834 · Cited by 121
“The former strategy of using CD28 costimulation to expand Treg (Figure 2C) was initially behind the ill-fated TGN1412 trial (59), suggesting it is extremely problematic.”
MethodOvercoming the challenges associated with CD3+ T-cell redirection in cancer
Singh, A. K., Dees, S., & Grewal, I. S. (2021) · British Journal of Cancer · doi:10.1038/s41416-020-01225-5 · Cited by 122
Zeiser, R., Socié, G., & Blazar, B. R. (2016) · British Journal of Haematology · doi:10.1111/bjh.14295 · Cited by 128
Kalia, V., Penny, L. A., Yuzefpolskiy, Y., Baumann, F. M., & Sarkar, S. (2015) · Immunity · doi:10.1016/j.immuni.2015.05.023 · Cited by 126
“In a phase I human clinical trial, CD28-SuperMAB administration was found to induce amassive cytokine storm (Hünig, 2012).”
BackgroundHow can we cure a heart “in flame”? A translational view on inflammation in heart failure
Hofmann, U., & Frantz, S. (2013) · Basic Research in Cardiology · doi:10.1007/s00395-013-0356-y · Cited by 118
Cytokine release assays: Current practices and future directions
Finco, D., Grimaldi, C., Fort, M., Walker, M., Kiessling, A., Wolf, B., Salcedo, T., Faggioni, R., Schneider, A., Ibraghimov, A., et al. (2014) · Cytokine · doi:10.1016/j.cyto.2013.12.009 · Cited by 106
Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies
Postel-Vinay, S. C., Aspeslagh, S., Lanoy, É., Robert, C., Soria, J., & Marabelle, A. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv550 · Cited by 117
Co-stimulatory and co-inhibitory pathways in cancer immunotherapy
O’Neill, R., & Cao, X. (2019) · Advances in cancer research · doi:10.1016/bs.acr.2019.03.003 · Cited by 110
“Early CD28 super-agonist trials were associated with serious toxicities and abandoned in phase I clinical trials [20, 21].”
BackgroundMonoclonal Antibodies: Past, Present and Future
Posner, J., Barrington, P. J., Brier, T., & Datta‐Mannan, A. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_323 · Cited by 130
Tabares, P., Berr, S., Römer, P. S., Chuvpilo, S., Matskevich, A. A., Tyrsin, D., Fedotov, Y., Einsele, H., Tony, H., & Hünig, T. (2014) · European Journal of Immunology · doi:10.1002/eji.201343967 · Cited by 97
Self-citationTargeting Cbl-b in cancer immunotherapy
Augustin, R. C., Bao, R., & Luke, J. J. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006007 · Cited by 101
“17 Coinhibitory receptors: CTLA-4 & PD-1 Antibodies against the CTLA-4 and PD-1 coinhibitory receptors have set a new benchmark for clinical benefit.”
BackgroundInfluentialHypersensitivity and immunologic reactions to biologics: opportunities for the allergist
Khan, D. A. (2016) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2016.05.013 · Cited by 91
Kerns, S. J., Belgur, C., Petropolis, D., Kanellias, M., Barrile, R., Sam, J., Weinzierl, T., Fauti, T., Freimoser-Grundschober, A., Eckmann, J., et al. (2021) · eLife · doi:10.7554/elife.67106 · Cited by 82
“It may also be of interest to other types of molecules such as super agonist CD28 antibodies, which induced a severe cytokine storm in the clinics (Hünig, 2012).”
BackgroundT lymphocytes and normal tissue responses to radiation
Schaue, D., & McBride, W. H. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00119 · Cited by 87
“There are risks in trying to manipulate immune control mechanisms as was seen with TGN1412 (Hunig, 2012), however, the potential is great and the prize could be a major increase in radiotherapeutic benefit in cancer treatment and ways to improve the outcome of radiological accidents and incidents.”
BackgroundFound In Translation: a machine learning model for mouse-to-human inference
Normand, R., Du, W., Briller, M., Gaujoux, R., Starosvetsky, E., Ziv-Kenet, A., Shalev-Malul, G., Tibshirani, R. J., & Shen-Orr, S. S. (2018) · Nature Methods · doi:10.1038/s41592-018-0214-9 · Cited by 76
CD28 co-stimulation: novel insights and applications in cancer immunotherapy
Lotze, M. T., Olejniczak, S. H., & Skokos, D. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-024-01061-1 · Cited by 91
Wang, L., Hoseini, S. S., Xu, H., Ponomarev, V., & Cheung, N. V. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0121 · Cited by 72
“A deeper understanding of the role of residual Fc functions, whether in ADCC or in CDC, should avoid unexpected acute or late effects in the clinical development of BsAbs, a requisite consideration since the lesson of TGN1412 (46, 47).”
BackgroundRegulatory T cells in acute and chronic kidney diseases
Sharma, R., & Kinsey, G. R. (2017) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00236.2017 · Cited by 69
Developability assessment as an early de-risking tool for biopharmaceutical development
Zurdo, J. (2013) · Pharmaceutical Bioprocessing · doi:10.4155/pbp.13.3 · Cited by 75
Jiménez, S. A., & Piera-Velázquez, S. (2013) · Autoimmunity Reviews · doi:10.1016/j.autrev.2013.04.004 · Cited by 65
The role of inflammation in progression of breast cancer: Friend or foe? (Review)
Allen, M. D., & Jones, J. L. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3075 · Cited by 74
PHARMACOTHERAPY FOR RHEUMATOID ARTHRITIS: NEW STRATEGY, NEW TARGETS
Nasonov, E. L. (2017) · Rheumatology Science and Practice · doi:10.14412/1995-4484-2017-409-419 · Cited by 68
Hong, E., Halman, J. R., Shah, A. B., Cedrone, E., Trưởng, N. V., Afonin, K. A., & Dobrovolskaia, M. A. (2019) · Molecules · doi:10.3390/molecules24061094 · Cited by 62
A Century of Radiation Therapy and Adaptive Immunity
Schaue, D. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00431 · Cited by 59
“A bitter lesson as to the power of the immunological synapse was learned from the disastrously trial of TGN1412, an anti-CD28 superagonist antibody that caused catastrophic organ failures in all subjects (161).”
BackgroundLiving in LALA land? Forty years of attenuating Fc effector functions
Hale, G. (2024) · Immunological Reviews · doi:10.1111/imr.13379 · Cited by 62
Liposomes with cyclic RGD peptide motif triggers acute immune response in mice
Wang, X., Wang, H., Jiang, K., Zhang, Y., Zhan, C., Ying, M., Zhang, M., Lu, L., Wang, R., Wang, S., et al. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.12.003 · Cited by 56
Current Landscape of Cancer Immunotherapy: Harnessing the Immune Arsenal to Overcome Immune Evasion
Mitra, A., Kumar, A., Amdare, N. P., & Pathak, R. (2024) · Biology · doi:10.3390/biology13050307 · Cited by 80
Zeng, Z., Yu, K., Chen, L., Li, W., Xiao, H., & Huang, Z. (2016) · Journal of Immunology Research · doi:10.1155/2016/8493767 · Cited by 59
“For example, Treg expansion with CD28 superagonists (CD28SA) improves wound healing and reduces the inflammatory damage in rodentMImodels [3, 8].”
CD69 Is the Crucial Regulator of Intestinal Inflammation: A New Target Molecule for IBD Treatment?
Radulovic, K., & Niess, J. H. (2015) · Journal of Immunology Research · doi:10.1155/2015/497056 · Cited by 70
“It has already been observed that targeting a single molecule on lymphocytes can lead to serious complications in humans, while the side effects were absent in all preclinical studies [135].”
BackgroundClinical development of monoclonal antibody-based drugs in HIV and HCV diseases
Flego, M., Ascione, A., Cianfriglia, M., & Vella, S. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-4 · Cited by 57
Response to 'Storm forecasting: additional lessons from the CD28 superagonist TGN1412 trial'
Hünig, T. (2012) · Nature reviews. Immunology · doi:10.1038/nri3192-c2 · Cited by 48
Self-citationCancer immunotherapy trials: leading a paradigm shift in drug development
Emens, L. A., Butterfield, L. H., Hodi, F. S., Marincola, F. M., & Kaufman, H. L. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0146-9 · Cited by 50
“TeGenero developed a first-in-class humanized superagonist monoclonal antibody specific for CD28, TGN1412 [12, 13].”
BackgroundThe rise and fall of the CD 28 superagonist TGN 1412 and its return as TAB 08: a personal account
Hünig, T. (2016) · The FEBS Journal · doi:10.1111/febs.13754 · Cited by 47
Self-citationGlinos, D. A., Soskic, B., Williams, C., Kennedy, A., Jostins, L., Sansom, D. M., & Trynka, G. (2020) · Genes and Immunity · doi:10.1038/s41435-020-00118-0 · Cited by 54
“revealed a powerful response to CD28-driven specifically by effector memory T cells [23].”
BackgroundResultDauner, A. L., Agrawal, P. B., Salvatico, J., Tapia, T. M., Dhir, V., Shaik, S. F., Drake, D. R., & Byers, A. M. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.03.099 · Cited by 42
TGN1412 Induces Lymphopenia and Human Cytokine Release in a Humanized Mouse Model
Weißmüller, S., Kronhart, S., Kreuz, D., Schnierle, B. S., Kalinke, U., Kirberg, J., Hanschmann, K.-M. O., & Waibler, Z. (2016) · PLoS ONE · doi:10.1371/journal.pone.0149093 · Cited by 45
“The disastrous outcome of the first-in-human clinical trial of TGN1412 put the predictive value of preclinical animal models into question and there is an ongoing debate on whether or not the severe adverse events induced were predictable by the preclinical studies conducted [4, 5].”
BackgroundCD30 as a Therapeutic Target for Lymphoma
Schirrmann, T., Steinwand, M., Wezler, X., ten Haaf, A., Tur, M. K., & Barth, S. (2013) · BioDrugs · doi:10.1007/s40259-013-0068-8 · Cited by 51
“Although combined application of T-cell-activating BimAbs achieved potent T-cell-mediated anti-tumor responses, it should be noted that targeting activating and costimulatory receptors like CD28 on T cells bears the intrinsic risk of provoking life-threatening cytokine-release syndromes [128].”
BackgroundA Transendocytosis Perspective on the CD28/CTLA-4 Pathway
Soskic, B., Qureshi, O. S., Hou, T., & Sansom, D. M. (2014) · Advances in immunology · doi:10.1016/b978-0-12-800147-9.00004-2 · Cited by 45
Fruchon, S., Mouriot, S., Thiollier, T., et al. (2014) · Nanotoxicology · doi:10.3109/17435390.2014.940406 · Cited by 38
“…effects of these organic nanoparticles in living organisms and on the other hand by the lessons from the deleterious first-in-man clinical trial of an immuno-modulatory monoclonal antibody in UK in 2006 (a multi-organ failure in healthy volunteers referred to as ‘‘cytokine storm’’) (Hünig, 2012).”
BackgroundStorm forecasting: additional lessons from the CD28 superagonist TGN1412 trial
Horvath, C. J., Andrews, L., Baumann, A., Black, L. E., Blanset, D. L., Cavagnaro, J. A., Hastings, K. L., Hutto, D., MacLachlan, T. K., Milton, M., et al. (2012) · Nature reviews. Immunology · doi:10.1038/nri3192-c1 · Cited by 41
Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications
Cabo, M., Offringa, R., Zitvogel, L., Kroemer, G., Muntasell, A., & Galluzzi, L. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1371896 · Cited by 37
“receiving the drug (even though the agent was injected at 1/500 of the highest dose safely employed in cynomolgus macaques).(160,161) Such an unfortunate occurrence sparked an”
BackgroundEmerging Therapies for Rheumatoid Arthritis
Kalden, J. R. (2016) · Rheumatology and Therapy · doi:10.1007/s40744-016-0032-4 · Cited by 39
A non-conserved amino acid variant regulates differential signalling between human and mouse CD28
Porciello, N., Grazioli, P., Campese, A. F., Kunkl, M., Caristi, S., Mastrogiovanni, M., Muscolini, M., Spadaro, F., Favre, C., Nunès, J. A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03385-8 · Cited by 37
Leach, M. W., Clarke, D. O., Dudal, S., Han, C., Li, C., Yang, Z., Brennan, F. R., Bailey, W. J., Chen, Y., Deslandes, A., et al. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2009 · Cited by 36
Oncolytic adenoviruses: a game changer approach in the battle between cancer and the immune system.
Cervera-Carrascón, V., Havunen, R., & Hemminki, A. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1595582 · Cited by 35
The Emerging Jamboree of Transformative Therapies for Autoimmune Diseases
Carballido, J. M., Regairaz, C., Rauld, C., Raad, L., Picard, D., & Kammuller, M. E. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00472 · Cited by 40
“This unfortunate event illustrates the fact that the balance between Treg and Teff cell responses in laboratory animals and humans and their response to superagonists can be significantly different (80, 83).”
BackgroundLi, Y. H., Carpenito, C., Wang, G., Surguladze, D., Forest, A., Malabunga, M., Murphy, M. Y., Zhang, Y., Sonyi, A., Chin, D., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0329-7 · Cited by 32
“While one physiological role of PD-L1 is believed to involve the suppression of T-cell activation to minimize damage to normal tissues by activated T cells [7, 8], more recent * Correspondence: yiwen.”
BackgroundStimulating T Cells Against Cancer With Agonist Immunostimulatory Monoclonal Antibodies
(2019) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2018.07.003 · Cited by 30
“The most infamous of these cases is the development of superagonist anti-CD28 TGN1412 (Hunig, 2012, Hunig, 2016).”
BackgroundInfluentialSchmidt, T., Willenborg, S., Hünig, T., Deeg, C. A., Sønderstrup, G., Hertl, M., & Eming, R. (2015) · Experimental Dermatology · doi:10.1111/exd.12919 · Cited by 31
Self-citationUnregulated antigen-presenting cell activation by T cells breaks self tolerance
Yi, J., Jung, J., Hong, S., Lee, J. Y., Han, D., Kim, K. S., Sprent, J., & Surh, C. D. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1818624116 · Cited by 35
“In considering how Treg removal causes naive T cells to respond to self ligands, recent studies on superagonistic CD28SA mAb [which caused florid pathology as TGN1412 in a clinical trial (40)] are instructive.”
BackgroundOX40R (TNFRSF4) bound to Fab 1A7
Yang, Y., Yeh, S. H., Madireddi, S., Matochko, W. L., Gu, C., Sanchez, P. P., Ultsch, M. H., Boenig, G. D. L., Harris, S. F., Leonard, B. C., et al. (2019) · mAbs · doi:10.1080/19420862.2019.1625662 · Cited by 48
“Dependence on TCRsignal is a key safety element of T cell co-stimulatory drugs.(21,22) Experiments with the r:Fab-IgG (Figure 3(h)), c:Fab-IgG (Figure 3(i)), and c:IgG-IgG (Figure 3(j)) formats in the FcγRIIa B7-1 co-stimulation assay agreed well with the r:FvIgG results, consistently demonstrating robust T cell activ…”
MethodRevisiting T-cell adhesion molecules as potential targets for cancer immunotherapy: CD226 and CD2
Jo, Y., Sim, H.-I., Yun, B., Park, Y., & Jin, H. (2024) · Experimental & Molecular Medicine · doi:10.1038/s12276-024-01317-9 · Cited by 36
Mechanistic basis of immunotherapies for type 1 diabetes mellitus
Chen, W., Xie, A., & Chan, L. (2013) · Translational research · doi:10.1016/j.trsl.2012.12.017 · Cited by 36
“It is important to note that attempts to target costimulatory pathways (eg, the use of CD28 superagonist antibody TGN1412) in humans have led to a life-threatening syndrome.(126) Thorough preclinical investigations are required to understand the therapeutic potential and possible toxicity of targeting costimulatory mo…”
Reed, D. M., Paschalaki, K. E., Starke, R. D., Mohamed, N. A., Sharp, G., Fox, B. J., Eastwood, D., Bristow, A., Ball, C., Vessillier, S., et al. (2015) · The FASEB Journal · doi:10.1096/fj.14-268144 · Cited by 32
“Thus, TGN1412 defined an urgent unmet need for improved bioassays to detect cytokine storm-inducing drugs (3, 4).”
BackgroundCassotta, M., Pistollato, F., & Battino, M. (2019) · ALTEX · doi:10.14573/altex.1910011 · Cited by 39
“A poignant example of this issue was the immunotherapy trial of TGN1412 (targeting CD28 signaling), which caused an unpredicted cytokine storm in six volunteers (Stebbings et al., 2007; Hunig, 2012).”
BackgroundSchaller, T. H., Snyder, D. J., Spasojević, I., Gedeon, P. C., Sanchez-Perez, L. A., & Sampson, J. H. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000213 · Cited by 28
Bispecific Antibodies in Prostate Cancer Therapy: Current Status and Perspectives
Heitmann, J. S., Pflügler, M., Jung, G., & Salih, H. R. (2021) · Cancers · doi:10.3390/cancers13030549 · Cited by 32
“However, the clinical development of such BiCos was thereafter impacted largely by the so called “Tegenero incident”, the deleterious cytokine release after application of a—notably monospecific and thus not target cell-restricted—“superagonistic” CD28 antibody [45,46].”
BackgroundInfluentialImpaired Arm Function and Finger Dexterity in a Nonhuman Primate Model of Stroke
McEntire, C. R. S., Choudhury, G. R., Torres, A., Steinberg, G. K., Redmond, D. E., & Daadi, M. M. (2016) · Stroke · doi:10.1161/strokeaha.115.012506 · Cited by 27
“homologies of a therapeutic target and validity for drug screening.(51,52) In addition, ethical, infrastructural, and finan-”
BackgroundThe bumpy road to evidence: why many research findings are lost in translation
Lüscher, T. F. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht396 · Cited by 29
Nouveau, L., Buatois, V., Cons, L., Chatel, L., Pontini, G., Pleche, N., & Ferlin, W. G. (2021) · European Journal of Immunology · doi:10.1002/eji.202149181 · Cited by 25
CD28: A New Drug Target for Immune Disease
Xia, S., Chen, Q., & Niu, B. (2019) · Current Drug Targets · doi:10.2174/1389450120666191114102830 · Cited by 27
Microbiota as Drivers and as Therapeutic Targets in Ocular and Tissue Specific Autoimmunity
Salvador, R., Zhang, A., Horai, R., & Caspi, R. R. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.606751 · Cited by 26
“SPF mice typically contain fewer memory cells than their wild-caught counterparts and in that regard their adult immune systems are more reminiscent of neonatal humans (Hunig, 2012).”
BackgroundKametani, Y., Katano, I., Miyamoto, A., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0179239 · Cited by 25
Bending, D., & Lab), M. O. (. (2018) · Clinical & Experimental Immunology · doi:10.1111/cei.13194 · Cited by 27
“Clinical & Experimental Immunology published by John Wiley & Sons Ltd on behalf of British Society for Immunology, Clinical and Experimental Immunology, 00:00–00 molecule on the surface of Treg which would, in turn, theoretically suppress non-Tregs [9].”
BackgroundDendritic cells enhance the antigen sensitivity of T cells
Garbi, N., & Kreutzberg, T. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00389 · Cited by 23
“Recently, Hünig’s group has shown that the proliferative response of human T cells to the superagonist CD28 TGN1412 antibody is also dependent on tonic TCR signaling maintained by MHC scanning (Romer et al., 2011; Hunig, 2012).”
BackgroundHernández, I. B., Kromhout, J. Z., Teske, E., Hennink, W. E., van Nimwegen, S. A., & Oliveira, S. (2021) · Theranostics · doi:10.7150/thno.55760 · Cited by 26
“This led, for instance, to the TGN1412 catastrophe in 2006 [177].”
BackgroundImmuno-Oncology: The Third Paradigm in Early Drug Development
Martín-Liberal, J., Hierro, C., de Olza, M. O., & Rodon, J. A. (2016) · Targeted Oncology · doi:10.1007/s11523-016-0471-4 · Cited by 25
“Lessons learned from this incident highlighted that animal models can fail to predict human toxicities due to the particularities of the immune system (IS) of each species [22].”
BackgroundBrennan, F. R., Cauvin, A. J., Tibbitts, J., & Wolfreys, A. (2014) · Drug Development Research · doi:10.1002/ddr.21173 · Cited by 23
“This led to catastrophic systemic organ failure in the normal volunteers in the trial [Suntharalingam et al., 2006; Hunig, 2012] and provided a “wake-up call” to the industry in highlighting that some mAbs have a real potential for human toxicity.”
BackgroundInfluentialVugmeyster, Y., Rohde, C. M., Perreault, M., Gimeno, R. E., & Singh, P. (2013) · mAbs · doi:10.4161/mabs.23826 · Cited by 24
“For example, following a single 1 mg/kg IV dose, the to significant safety concerns, as exemplified by the widely publicized case of TGN1412, an agonistic antibody against a T cell target.(5) On the other hand, a starting dose that is too low can lead to the need for clinical testing of a wide dose range, which is ass…”
BackgroundWaight, J. D., Gombos, R. B., & Wilson, N. S. (2017) · Human Antibodies · doi:10.3233/hab-160308 · Cited by 22
“…receptors as well as their cognate ligands, provides challenges on how therapeutic antibodies optimally engage these receptors to achieve a signaling threshold that modulates an immunological outcome, while avoiding the potential immune-related adverse events associated with superagonists [80].”
Georgiadou, A., Dunican, C., Soro-Barrio, P., Lee, H. J., Kaforou, M., & Cunnington, A. J. (2022) · eLife · doi:10.7554/elife.70763 · Cited by 21
Integrated Single-Cell Transcriptomic Atlas of Human Kidney Endothelial Cells
Zhang, K., Kan, H., Mao, A., Yu, F., Li, G., Zhou, T., Feng, L., & Ma, X. (2024) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000000000320 · Cited by 23
“53,54 Thus, it is necessary to explore the similarities and differences between mouse and human kidney ECs.”
BackgroundGilham, D. E., Anderson, J., Bridgeman, J. S., Hawkins, R. E., Exley, M. A., Stauss, H. J., Maher, J. F., Pulè, M. A., Sewell, A. K., Bendle, G. M., et al. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.024 · Cited by 23
“27 Both of these high-profile events raised major questions concerning the safety (separately) of retroviral vectors and immune-directed therapies that required extensive review and re-review of the CEA and CD19 CAR T-cell protocols.”
CD28 between tolerance and autoimmunity: the side effects of animal models
Porciello, N., Kunkl, M., & Tuosto, L. (2018) · F1000Research · doi:10.12688/f1000research.14046.1 · Cited by 20
T-Cell Costimulatory Blockade in Organ Transplantation
Maltzman, J. S., & Turka, L. A. (2013) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a015537 · Cited by 20
“…evidence that antiCD28 blocking agents would have a similar effect, caution is likely to be the byword in this area, and extensive preclinical testing that takes into account species-specific differences in the types of T cells that express CD28 will be required (Eastwood et al. 2010; Hunig 2012).”
BackgroundChallenges and opportunities for monoclonal antibody therapy in veterinary oncology
Beirão, B. C. B., Raposo, T. P., Jain, S., Hupp, T. R., & Argyle, D. J. (2016) · The Veterinary Journal · doi:10.1016/j.tvjl.2016.11.005 · Cited by 24
XGSEA: CROSS-species gene set enrichment analysis via domain adaptation
Cai, M., Nguyen, C. H., Mamitsuka, H., & Li, L. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa406 · Cited by 17
Kenter, M. J. H., & Cohen, A. F. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12605 · Cited by 17
The Importance and Clinical Relevance of Surfaces in Tissue Culture
Hickman, G. J., Boocock, D. J., Pockley, A. G., & Perry, C. C. (2016) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.5b00403 · Cited by 23
Carratalá, J. V., Cano‐Garrido, O., Sánchez, J. M., Membrado, C., Pérez, E., Conchillo‐Solé, O., Daura, X., Sánchez‐Chardi, A., Villaverde, A., Arı́s, A., et al. (2020) · New Biotechnology · doi:10.1016/j.nbt.2020.02.001 · Cited by 17
Translating pharmacology models effectively to predict therapeutic benefit
Dudal, S., Bissantz, C., Caruso, A., David‐Pierson, P., Driessen, W. H. P., Koller, E., Krippendorff, B., Lechmann, M., Olivares‐Morales, A., Paehler, A., et al. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.03.009 · Cited by 22
B Cell Epitope-Based Vaccination Therapy
Kametani, Y., Miyamoto, A., Tsuda, B., & Tokuda, Y. (2015) · Antibodies · doi:10.3390/antib4030225 · Cited by 21
“mouse and monkey models and caused antibody-induced cytokine storms in healthy donors in clinical trials [85].”
BackgroundFrom Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely
Day, D., Monjazeb, A. M., Sharon, E., Ivy, S. P., Rubin, E. H., Rosner, G. L., & Butler, M. O. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3064 · Cited by 17
“In immunotherapy research, an additional barrier arises from inherent differences in immune systems across species and tumor antigen repertoire, leading to poor recapitulation of host immune effects, as highlighted by unforeseen severe immune-mediated toxicities in the first-in-human (FIH) study of a CD28 agonist (77).”
Background
Metadata
- Authors
- Hünig, T.
- Affiliations
- University of Würzburg (DE)
- Corresponding author
- Hünig, Thomas
- Venue
- Nature Reviews Immunology
- Published
- 2012-04-10
- Volume
- 12
- Issue
- 5
- Pages
- 317-318
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- OpenAlex
- W2080341180
- Cited by
- 194
- References
- 14
- Citations by year
- 2026: 8 · 2025: 2 · 2024: 14 · 2023: 11 · 2022: 3 · 2021: 16 · 2020: 10 · 2019: 17 · 2018: 16 · 2017: 19 · 2016: 20 · 2015: 21 · 2014: 15 · 2013: 16 · 2012: 6
- FWCI
- 14.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Immunology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- TGN1412, cytokine release syndrome
- MeSH terms
- Adult, Animals, Clinical Trials as Topic, Humans, Leukocytes, Mononuclear, Male, Clinical Trials, Phase I as Topic, Young Adult, Immunomodulation, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.